E. Laukhtina, D. D’andrea, B. Pradère, D. Enikeev, M. Abufaraj, S. Shariat
{"title":"预测患者膀胱内免疫治疗反应的预后模型","authors":"E. Laukhtina, D. D’andrea, B. Pradère, D. Enikeev, M. Abufaraj, S. Shariat","doi":"10.1080/23808993.2020.1768845","DOIUrl":null,"url":null,"abstract":"ABSTRACT Introduction Approximately 30–60% of patients treated with Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer (NMIBC) eventually experience disease recurrence within 2 years. Parsimonious use of BCG and accurate identification of those patients who might benefit from this therapy is of paramount importance in order to avoid BCG wastage, improve patient counseling regarding alternative therapy, patient’s survival and quality of life. We summarized the current literature on predictive and prognostic models on intravesical BCG therapy for NMIBC. Areas covered Clinicopathologic features are the strongest predictors of BCG response. In addition, several tissue, serum and urinary biomarkers have been investigated. However, they have not been shown to be robust enough to be implemented in daily clinical routine. Therefore, genetic and epigenetic markers and features of the tumor microenvironment have been investigated. The relationship between Th1 and Th2 microenvironments, as well as its related serum and urine biomarkers, was shown to play an important role in prediction of response to BCG treatment. Expert opinion No single tumor biomarker has been shown to be robust enough to change clinical decision making. Discoveries in the genetic signature profile of bladder cancer and immunological pathways represent the new frontiers in biomarker discovery and possible improvement in patient selection in the era of personalized medicine.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2020.1768845","citationCount":"1","resultStr":"{\"title\":\"Prognostic models to help predict patient responses to intravesical immunotherapy\",\"authors\":\"E. Laukhtina, D. D’andrea, B. Pradère, D. Enikeev, M. Abufaraj, S. Shariat\",\"doi\":\"10.1080/23808993.2020.1768845\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ABSTRACT Introduction Approximately 30–60% of patients treated with Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer (NMIBC) eventually experience disease recurrence within 2 years. Parsimonious use of BCG and accurate identification of those patients who might benefit from this therapy is of paramount importance in order to avoid BCG wastage, improve patient counseling regarding alternative therapy, patient’s survival and quality of life. We summarized the current literature on predictive and prognostic models on intravesical BCG therapy for NMIBC. Areas covered Clinicopathologic features are the strongest predictors of BCG response. In addition, several tissue, serum and urinary biomarkers have been investigated. However, they have not been shown to be robust enough to be implemented in daily clinical routine. Therefore, genetic and epigenetic markers and features of the tumor microenvironment have been investigated. The relationship between Th1 and Th2 microenvironments, as well as its related serum and urine biomarkers, was shown to play an important role in prediction of response to BCG treatment. Expert opinion No single tumor biomarker has been shown to be robust enough to change clinical decision making. Discoveries in the genetic signature profile of bladder cancer and immunological pathways represent the new frontiers in biomarker discovery and possible improvement in patient selection in the era of personalized medicine.\",\"PeriodicalId\":12124,\"journal\":{\"name\":\"Expert Review of Precision Medicine and Drug Development\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2020-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/23808993.2020.1768845\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Precision Medicine and Drug Development\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/23808993.2020.1768845\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Precision Medicine and Drug Development","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23808993.2020.1768845","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Prognostic models to help predict patient responses to intravesical immunotherapy
ABSTRACT Introduction Approximately 30–60% of patients treated with Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer (NMIBC) eventually experience disease recurrence within 2 years. Parsimonious use of BCG and accurate identification of those patients who might benefit from this therapy is of paramount importance in order to avoid BCG wastage, improve patient counseling regarding alternative therapy, patient’s survival and quality of life. We summarized the current literature on predictive and prognostic models on intravesical BCG therapy for NMIBC. Areas covered Clinicopathologic features are the strongest predictors of BCG response. In addition, several tissue, serum and urinary biomarkers have been investigated. However, they have not been shown to be robust enough to be implemented in daily clinical routine. Therefore, genetic and epigenetic markers and features of the tumor microenvironment have been investigated. The relationship between Th1 and Th2 microenvironments, as well as its related serum and urine biomarkers, was shown to play an important role in prediction of response to BCG treatment. Expert opinion No single tumor biomarker has been shown to be robust enough to change clinical decision making. Discoveries in the genetic signature profile of bladder cancer and immunological pathways represent the new frontiers in biomarker discovery and possible improvement in patient selection in the era of personalized medicine.
期刊介绍:
Expert Review of Precision Medicine and Drug Development publishes primarily review articles covering the development and clinical application of medicine to be used in a personalized therapy setting; in addition, the journal also publishes original research and commentary-style articles. In an era where medicine is recognizing that a one-size-fits-all approach is not always appropriate, it has become necessary to identify patients responsive to treatments and treat patient populations using a tailored approach. Areas covered include: Development and application of drugs targeted to specific genotypes and populations, as well as advanced diagnostic technologies and significant biomarkers that aid in this. Clinical trials and case studies within personalized therapy and drug development. Screening, prediction and prevention of disease, prediction of adverse events, treatment monitoring, effects of metabolomics and microbiomics on treatment. Secondary population research, genome-wide association studies, disease–gene association studies, personal genome technologies. Ethical and cost–benefit issues, the impact to healthcare and business infrastructure, and regulatory issues.